Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19

To reduce Coronavirus Disease 2019 (COVID-19)-related mortality and morbidity, widely available oral COVID-19 treatments are urgently needed. Certain antidepressants, such as fluvoxamine or fluoxetine, may be beneficial against COVID-19. We included 388,945 adult inpatients who tested positive for S...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoertel, Nicolas, Sánchez-Rico, Marina, Kornhuber, Johannes, Gulbins, Erich, Reiersen, Angela M., Lenze, Eric J., Fritz, Bradley A., Jalali, Farid, Mills, Edward J., Cougoule, Céline, Carpinteiro, Alexander, Mühle, Christiane, Becker, Katrin Anne, Boulware, David R., Blanco, Carlos, Alvarado, Jesús M., Strub-Wourgaft, Nathalie, Lemogne, Cédric, Limosin, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572995/
https://www.ncbi.nlm.nih.gov/pubmed/36233753
http://dx.doi.org/10.3390/jcm11195882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572995/
https://www.ncbi.nlm.nih.gov/pubmed/36233753
http://dx.doi.org/10.3390/jcm11195882

Ejemplares similares